GlaxoSmithKline and Pfizer Create New HIV-Focused Company - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

GlaxoSmithKline and Pfizer Create New HIV-Focused Company

ePT--the Electronic Newsletter of Pharmaceutical Technology

Pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer announced on April 16, 2009 that they are joining forces to tackle HIV. They are creating a company that will specialize in the research, development, and access of HIV treatments by combining existing products, new products already in each company’s pipeline, and existing not-for-profit access programs. Research and development (R&D) of new treatments will be a central focus of the new company, and R&D services will be contracted directly from GSK and Pfizer.

The new company’s main goal is to become an industry leader with a combined product portfolio that includes 11 products already in the market, including GSK's Combivir (lamivudine, zidovudine), Kivexa (abacavir/lamivudine), and Pfizer's Selzentry/Celsentri (maraviroc tablets), and six products currently in development. “By combining Pfizer’s and GlaxoSmithKline’s complementary strengths and capabilities, we are creating a new global leader in HIV and reaffirming our ongoing commitment to the treatment of the disease,” stated Jeff Kindler, Pfizer CEO, in a company press release.

Access to HIV treatments will also be an important focus for the new company. A statement on the HIV Futures company website assures that “not-for-profit pricing for HIV medicines will continue for those countries most in need, and the new company will continue to facilitate new voluntary licenses to diversity production and expand capacity in these markets.” The company will also address the continuing need for research into the global treatment of children living with HIV.

Both GSK and Pfizer have HIV drug access programs already in place around the world. “HIV remains a global threat with increasing incidence and viral resistance. This new company will be better placed to meet these challenges and improve access to treatments,” stated Andrew Witty, GSK chief executive officer, in a company press release. “The new company can reach more patients and accomplish much more for the treatment of HIV globally than either company on its own,” stated Kindler.

More information regarding the new HIV-focused company can be found at


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here